DrugRepV|Encyclopedia for antivirals

DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.

Total number of Records for Retroviridae are 803

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Assay	Activity	Clinical Status	References
DrugRepV_6481	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma \| Gastrointestinal stromal tumor	Human immunodeficiency virus	NL4-3	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_6482	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Human immunodeficiency virus	NL4-3	Luciferase reporter assay	Decrease (50 %)	Approved	28240606
DrugRepV_6483	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Human immunodeficiency virus	HXB2 luciferase reporter virus	Luciferase reporter assay	Decrease (60 %)	Approved	26807966
DrugRepV_6484	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Human immunodeficiency virus	JR-FL luciferase reporter virus	Luciferase reporter assay	Decrease (90 %)	Approved	26807966
DrugRepV_6485	Saracatinib	Anticancer	Osteosarcoma \| Ovarian Cancer \| Fallopian Tube Cancer \| Primary Peritoneal Cancer	Human immunodeficiency virus	HXB2 luciferase reporter virus	Luciferase reporter assay	Decrease (60 %)	Investigational	26807966
DrugRepV_6486	Saracatinib	Anticancer	Osteosarcoma \| Ovarian Cancer \| Fallopian Tube Cancer \| Primary Peritoneal Cancer	Human immunodeficiency virus	JR-FL luciferase reporter virus	Luciferase reporter assay	Decrease (90 %)	Investigational	26807966
DrugRepV_6487	KX2-391	NA	Colon cancer \| Pancreatic cancer \| Prostate cancer \| Breast cancer	Human immunodeficiency virus	HXB2 luciferase reporter virus	Luciferase reporter assay	Decrease (80 %)	Investigational	26807966
DrugRepV_6488	KX2-391	NA	Colon cancer \| Pancreatic cancer \| Prostate cancer \| Breast cancer	Human immunodeficiency virus	JR-FL luciferase reporter virus	Luciferase reporter assay	Decrease (90 %)	Investigational	26807966
DrugRepV_6489	Src inhibitor-1	Anticancer	Pancreatic cancer \| Breast cancer \| Stomach cancer	Human immunodeficiency virus	HXB2 luciferase reporter virus	Luciferase reporter assay	Decrease (60 %)	NA	26807966
DrugRepV_6490	Src inhibitor-1	Anticancer	Pancreatic cancer \| Breast cancer \| Stomach cancer	Human immunodeficiency virus	JR-FL luciferase reporter virus	Luciferase reporter assay	Decrease (75 %)	NA	26807966
DrugRepV_6491	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome \| Hepatitis B virus	Human immunodeficiency virus	NA	Modelling based approach	Decrease (50 %)	Approved	26796142
DrugRepV_6492	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA	Modelling based approach	Decrease (50 %)	Approved	26796142
DrugRepV_6493	Tenofovir disoproxil Fumarate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA	Modelling based approach	Decrease (50 %)	NA	26796142
DrugRepV_6494	Decitabine	Antineoplastic and Immunomodulating Agents	Myelodysplastic syndrome	Human immunodeficiency virus	NA	Plaque assay	Decrease (50 %)	Approved	20610712
DrugRepV_6495	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer \| Non-small cell lung cance \| Adenocarcinoma of the pancreas	Human immunodeficiency virus	NA	Plaque assay	Decrease (50 %)	Approved	20610712
DrugRepV_6496	Decitabine	NA	Myelodysplastic syndromes +Different types of Cancer	Human immunodeficiency virus	NA	Plaque assay	Decrease (73 %)	NA	20610712
DrugRepV_6497	Hydroxyurea	Antineoplastic and Immunomodulating Agents	Melanoma \| Chronic myelocytic leukemia \| Ovary carcinoma \| Sickle-cell anemia	Human immunodeficiency virus	NA	Plaque assay	Decrease (10 %)	Approved	20610712
DrugRepV_6498	Decitabine	NA	NA	Human immunodeficiency virus	NA	Plaque assay	Decrease (75 %)	NA	20610712
DrugRepV_6499	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer \| Non-small cell lung cance \| Adenocarcinoma of the pancreas	Human immunodeficiency virus	NA	Plaque assay	Decrease (100 %)	Approved	20610712
DrugRepV_6500	Decitabine	NA	Myelodysplastic syndromes +Different types of Cancer	Human immunodeficiency virus	NA	Real-time PCR	Decrease	NA	20610712
DrugRepV_6501	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1ADA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	15385252
DrugRepV_6502	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1ADA	Enzyme-linked immunosorbent assay	Decrease (71-96 %)	Approved, Investigational	15385252
DrugRepV_6503	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1ADA	Enzyme-linked immunosorbent assay	Decrease (85 %)	Approved, Investigational	15385252
DrugRepV_6504	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1BaL	Enzyme-linked immunosorbent assay	Decrease (65 %)	Approved, Investigational	15385252
DrugRepV_6505	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-189.6	Enzyme-linked immunosorbent assay	Decrease (NA %)	Approved, Investigational	15385252
DrugRepV_6506	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1JR-FL env	Luciferase reporter assay	Decrease (80 %)	Approved, Investigational	15385252
DrugRepV_6507	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1 VSV-G env	Luciferase reporter assay	Decrease (60 %)	Approved, Investigational	15385252
DrugRepV_6508	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1 AML-V env	Luciferase reporter assay	No significant effect (40 %)	Approved, Investigational	15385252
DrugRepV_6509	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever \| Typhus fever and the typhus group \| Q fever \| Rickettsial pox \| tick fevers caused by Rickettsiae \| Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1 VSV-G env	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	15385252
DrugRepV_6510	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6511	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6512	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6513	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	ECL RT biochemical assay	Decrease (50 %)	Approved	24379202
DrugRepV_6514	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6515	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6516	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6517	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	ECL RT biochemical assay	Decrease (50 %)	Approved	24379202
DrugRepV_6518	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6519	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6520	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6521	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	ECL RT biochemical assay	Decrease (50 %)	Approved	24379202
DrugRepV_6522	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6523	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6524	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6525	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type	HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6526	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6527	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6528	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6529	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N	HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6530	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6531	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6532	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6533	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6534	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6535	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6536	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6537	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C	HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6538	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6539	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6540	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (90 %)	Approved	24419350
DrugRepV_6541	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (90 %)	Approved, Investigational	24419350
DrugRepV_6542	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	HIV-2pROD10	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6543	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	HIV-2pROD10	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6544	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	HIV-2pROD10	Enzyme-linked immunosorbent assay	Decrease (90 %)	Approved	24419350
DrugRepV_6545	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	HIV-2pROD10	Enzyme-linked immunosorbent assay	Decrease (90 %)	Approved, Investigational	24419350
DrugRepV_6546	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6547	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6548	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (90 %)	Approved	24419350
DrugRepV_6549	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	HIV-1LAI	Enzyme-linked immunosorbent assay	Decrease (90 %)	Approved, Investigational	24419350
DrugRepV_6550	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	PHA+IL2	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6551	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	PHA+IL2	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6552	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	PHA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6553	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	PHA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6554	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6555	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6556	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	xxLAI	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6557	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	M184V	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6558	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	K65R	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6559	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	L74V	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6560	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	A62V/V75I/F77L/F116Y/Q151M	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6561	Tofacitinib	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Human immunodeficiency virus	4XAZT(D67N/K70R/T215Y/K219Q)	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24419350
DrugRepV_6562	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	xxLAI	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6563	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	M184V	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6564	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	K65R	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6565	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	L74V	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6566	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	A62V/V75I/F77L/F116Y/Q151M	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6567	Ruxolitinib	Antineoplastic and Immunomodulating Agents	Bone marrow cancer \| Myelofibrosis	Human immunodeficiency virus	4XAZT(D67N/K70R/T215Y/K219Q)	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24419350
DrugRepV_6568	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved, Investigational	20810732
DrugRepV_6569	Amprenavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6570	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6571	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6572	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved, Investigational	20810732
DrugRepV_6573	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6574	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6575	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved, Investigational	20810732
DrugRepV_6576	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre	p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6577	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6578	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6579	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6580	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6581	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6582	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6583	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6584	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6585	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6586	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6587	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6588	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6589	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6590	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6591	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6592	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6593	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6594	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6595	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6596	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6597	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6598	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6599	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6600	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6601	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6602	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6603	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6604	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6605	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6606	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6607	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6608	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6609	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6610	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6611	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6612	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6613	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6614	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6615	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6616	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6617	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6618	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6619	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6620	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6621	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6622	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6623	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6624	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6625	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6626	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6627	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6628	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6629	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6630	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6631	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6632	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6633	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6634	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6635	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6636	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6637	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6638	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6639	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6640	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6641	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6642	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6643	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6644	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6645	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6646	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6647	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6648	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6649	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6650	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6651	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6652	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6653	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6654	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6655	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6656	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6657	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6658	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6659	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6660	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6661	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6662	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6663	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6664	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6665	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6666	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6667	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6668	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6669	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6670	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6671	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6672	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6673	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6674	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6675	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6676	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6677	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6678	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6679	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6680	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6681	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6682	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6683	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6684	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6685	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6686	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6687	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6688	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6689	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6690	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6691	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6692	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6693	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6694	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6695	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6696	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6697	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6698	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6699	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6700	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6701	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6702	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6703	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6704	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6705	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6706	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6707	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6708	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6709	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6710	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6711	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6712	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6713	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6714	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6715	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6716	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6717	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6718	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6719	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6720	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6721	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6722	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6723	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6724	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6725	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6726	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6727	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6728	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6729	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6730	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6731	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6732	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6733	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6734	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6735	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6736	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6737	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6738	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6739	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6740	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6741	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6742	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6743	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6744	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6745	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6746	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6747	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6748	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6749	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6750	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6751	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6752	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6753	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6754	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6755	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6756	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6757	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6758	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6759	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6760	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6761	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6762	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6763	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6764	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6765	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6766	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6767	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6768	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6769	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6770	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6771	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6772	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6773	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6774	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6775	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6776	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6777	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6778	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6779	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6780	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6781	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6782	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6783	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6784	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6785	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6786	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6787	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6788	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6789	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6790	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6791	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6792	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6793	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6794	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6795	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6796	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6797	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6798	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6799	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6800	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6801	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6802	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6803	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6804	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6805	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6806	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6807	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6808	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6809	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6810	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6811	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6812	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6813	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6814	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6815	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6816	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6817	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6818	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6819	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6820	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6821	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6822	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6823	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6824	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6825	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6826	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6827	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6828	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6829	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6830	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6831	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6832	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6833	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6834	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6835	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6836	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6837	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6838	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6839	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6840	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6841	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6842	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6843	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6844	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6845	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6846	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6847	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6848	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6849	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6850	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6851	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6852	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6853	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6854	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6855	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6856	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6857	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6858	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6859	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6860	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K	Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6861	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6862	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6863	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6864	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6865	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6866	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K	Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6867	4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6868	4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6869	4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6870	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6871	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6872	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6873	4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6874	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6875	4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6876	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6877	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6878	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6879	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6880	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6881	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6882	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6883	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6884	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6885	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6886	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6887	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6888	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6889	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6890	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6891	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6892	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6893	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6894	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6895	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6896	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA	MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6897	Phorbol	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6898	Phorbol-12-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6899	Phorbol-12-decanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6900	Phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6901	Phorbol-13-butyrate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6902	Phorbol-13-decanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6903	Phorbol-13-tetradecanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6904	Phorbol-12,13-diacetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6905	Phorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6906	Phorbol-12,13- dihexanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6907	Phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6908	4α-phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6909	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	Phase II	25970561
DrugRepV_6910	12-O-tetradecanoyl-4γ-phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6911	12-O- tiglylphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6912	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6913	Phorbol-13,20-diacetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6914	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6915	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6916	Phorbol-12,13,20-triacetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6917	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6918	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6919	12-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6920	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6921	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6922	Ingenol	Dermatologicals	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6923	Ingenol-3-mebutate	Dermatologicals	Actinic keratosis	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6924	Ingenol-3,20-dibenzoate	Dermatologicals	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6925	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	Investigational	25970561
DrugRepV_6926	AzidoThymidine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6927	Phorbol	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6928	Phorbol-12-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6929	Phorbol-12-decanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6930	Phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6931	Phorbol-13-butyrate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6932	Pphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6933	Phorbol-13-tetradecanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6934	Phorbol-12,13-diacetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6935	Phorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6936	Phorbol-12,13- dihexanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6937	Phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6938	4α-phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6939	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	Phase II	25970561
DrugRepV_6940	12-O-tetradecanoyl-4?-phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6941	12-O- tiglylphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6942	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6943	Phorbol-13,20-diacetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6944	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6945	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6946	Phorbol-12,13,20-triacetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6947	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6948	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6949	12-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6950	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6951	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6952	Ingenol	Dermatologicals	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6953	Ingenol-3-mebutate	Dermatologicals	Actinic keratosis	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6954	Ingenol-3,20-dibenzoate	Dermatologicals	NA	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6955	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	Investigational	25970561
DrugRepV_6956	AzidoThymidine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	ROD	MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6957	FGI-106	NA	NA	Human immunodeficiency virus	NA	Luciferase assay	Decrease (50 %)	NA	19523489
DrugRepV_6958	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Approved	15200845
DrugRepV_6959	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome \| Hepatitis B virus	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Approved	15200845
DrugRepV_6960	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Approved	15200845
DrugRepV_6961	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Approved, Investigational	15200845
DrugRepV_6962	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA	NA	Decrease (95 %)	Approved	15200845
DrugRepV_6963	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Approved	15200845
DrugRepV_6964	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6965	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6966	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6967	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6968	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6969	L-Neplanocin A	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6970	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6971	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6972	Cyclopentenyl nucleosides	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6973	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6974	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6975	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6976	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6977	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6978	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6979	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	11689085
DrugRepV_6980	Octadecyloxyethyl benzyl 9-[(2-phosphonomethoxy)ethyl]guanine	NA	NA	Human immunodeficiency virus	NA	RT-PCR	Decrease (50 %)	NA	27933957
DrugRepV_6981	3-azido-2,3-dideoxyuridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6982	1-(4-azido-5-hydroxyoxolan-2-yl)-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6983	1-(4-azido-5-hydroxyoxolan-2-yl)-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6984	2- deoxy-5-fluorouridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6985	2- deoxy-5-bromouridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6986	2-deoxy-5-iodouridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6987	3-Azido-2,3-dideoxy-5-aminouridine Hydrochloride	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6988	3-Azido-2,3-dideoxy-5-(methylamino)uridine hydrochloride	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6989	3-Azido-2,3-dideoxy-5-(dimethylamino)uridine hydrochloride	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6990	3-Azido-2,3-dideoxy-5-hydroxyuridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6991	3-Azido-2,3-dideoxy-5-methoxyuridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6992	3-Azido-2,3-dideoxy-5-ethoxyuridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6993	3-Azido-2,3-dideoxy-5-(2-propynyloxy)uridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6994	3-Azido-2,3-dideoxy-5-(propenyloxy)uridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6995	3-Azido-2,3-dideoxy-5-[(cyanomethyl)oxy]uridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6996	3-Azido-2,3-dideoxy-5-thiocyanatouridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6997	3-Azido-2,3-dideoxy-5-(methylthio)uridine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6998	2-deoxycytidine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6999	2-deoxy-5-fluorocytidine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7000	2,-deoxy-5-methylcytidine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7001	3-(3-Oxo-l-propenyI)-3-azido-3-deoxyThymidine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7002	3-Azido-3-deoxy-6-azaThymidine	NA	NA	Human immunodeficiency virus	LAV	RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7942	DHBNH	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7943	3-[(E)-{[(3,4-dihydroxyphenyl)formamido]imino}methyl]-[1,1'-biphenyl]-4-carboxylic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7944	(3E)-3-{2-[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]hydrazin-1-ylidene}-2,3-dihydro-1H-indol-2-one	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7945	4-[2-[(2-hydroxy-1H-indol-3-yl)diazenyl]-1,3-thiazol-4-yl]benzonitrile	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7946	NSC727447	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7947	NSC732665	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7948	2-(3,4-Dihydroxyphenyl)-1,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7949	2-(3,4-dihydroxybenzamido)-N-(pyridin-2-yl)-4H,5H,6H,7H,8H-cyclohepta[b]thiophene-3-carboxamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7950	5-(3,4-dihydroxyphenyl)-4-oxa-8-thia-6-azatricyclo[7.4.0.0�,?]trideca-1(9),2(7),5,10,12-pentaen-3-one	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7951	(E)-3-(3,4-dihydroxyphenyl)-N-[(Z)-octadec-9-enyl]prop-2-enamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7952	4-Butoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7953	4-Butyl-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7954	4-butyl-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7955	2-fluoro-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7956	N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7957	4-amino-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7958	3,4-dimethoxy-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7959	3,4-dihydroxy-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7960	2-fluoro-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7961	N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7962	4-amino-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7963	3,4-dimethoxy-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7964	3,4-dihydroxy-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7965	4-butyl-N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7966	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-2-fluorobenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7967	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7968	4-amino-N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7969	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dimethoxybenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7970	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dihydroxybenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7971	N-{5,7-diphenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dihydroxybenzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7972	N-[7-(3,4-dihydroxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7973	N-benzoyl-N-[7-(3,4-dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]benzamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7974	N-(3,4-dihydroxyphenyl)-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7975	N-(3,4-dihydroxyphenyl)-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	32151066
DrugRepV_7988	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7989	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7990	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7991	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7992	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7993	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7994	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7995	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7996	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7997	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7998	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_7999	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8000	3-(1-benzyl-1H-indol-3-yl)-2-(6-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}-4-(2-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}ethyl)-4-nitrohexanamido)propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8001	2-{6-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8002	4-{[3-(2-carboxy-2-{6-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}ethyl)-1H-indol-1-yl]methyl}benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8003	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8004	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8005	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8006	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8007	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8008	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8009	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8010	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8011	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8012	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8013	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8014	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8015	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8016	3-(1-benzyl-1H-indol-3-yl)-2-(6-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}-4-(2-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}ethyl)-4-nitrohexanamido)propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8017	2-{6-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8018	4-{[3-(2-carboxy-2-{6-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}ethyl)-1H-indol-1-yl]methyl}benzoic acid	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8019	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31809045
DrugRepV_8055	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8056	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8057	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8058	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8059	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8060	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8061	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8062	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8063	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8064	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8065	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8066	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8067	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8068	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8069	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8070	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8071	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8072	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8073	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8074	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8075	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8076	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8077	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8078	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8079	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8080	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8081	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8082	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8083	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8084	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8085	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8086	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8087	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8088	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	NA	Decrease (50 %)	NA	31599568
DrugRepV_8089	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8090	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8091	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8092	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8093	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8094	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8095	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8096	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8097	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8098	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8099	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8100	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8101	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8102	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8103	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8104	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8105	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8106	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8107	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8108	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8109	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8110	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K	NA	Decrease (50 %)	NA	31599568
DrugRepV_8111	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8112	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8113	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8114	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8115	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8116	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8117	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8118	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8119	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8120	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8121	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8122	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8123	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8124	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8125	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8126	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8127	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8128	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8129	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8130	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8131	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8132	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N	NA	Decrease (50 %)	NA	31599568
DrugRepV_8311	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Human immunodeficiency virus	NA	Western blot	Decrease (50 %)	Approved	32132561
DrugRepV_8312	Lansoprazole	Alimentary Tract and Metabolism	Gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease	Human immunodeficiency virus	NA	Western blot	Decrease (50 %)	Approved, Investigational	32132561
DrugRepV_8313	Pantoprazole	Alimentary Tract and Metabolism	Gastroesophageal reflux disease	Human immunodeficiency virus	NA	Western blot	Decrease (50 %)	Approved	32132561
DrugRepV_8314	Rabeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use	Human immunodeficiency virus	NA	Western blot	Decrease (50 %)	Approved, Investigational	32132561
DrugRepV_8315	Tenatoprazole	NA	NA	Human immunodeficiency virus	NA	Western blot	Decrease (50 %)	NA	32132561
DrugRepV_8316	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer \| Non-small cell lung cance \| Adenocarcinoma of the pancreas	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Approved	31866007
DrugRepV_8317	Roscovitine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31866007
DrugRepV_8318	Quinacrine	NA	Malaria \| Giardiasis \| Cutaneous leishmaniasis \| Management of malignant effusions	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Investigational	31866007
DrugRepV_8319	Kenpaullone	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31866007
DrugRepV_8320	SB743921	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31866007
DrugRepV_8321	3-Deazauridine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31866007
DrugRepV_8322	2�-C-Methylcytidine	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	31866007
DrugRepV_8339	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8340	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8341	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8342	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8343	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8344	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8345	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8346	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8347	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8348	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8349	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8350	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8351	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8352	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8353	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8354	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8355	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8356	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8357	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8358	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8359	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8360	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8361	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8362	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8363	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8364	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8365	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8366	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8367	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8368	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8369	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8370	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8371	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8372	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8373	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8374	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8375	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8376	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8377	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8378	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8379	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8380	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8381	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8382	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8383	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8384	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8385	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8386	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8387	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8388	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8389	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8390	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8391	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8392	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8393	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8394	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8395	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8396	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8397	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8398	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8399	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8400	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8401	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8402	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8403	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8404	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8405	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8406	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8407	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8408	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8409	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8410	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8411	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8412	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8413	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8414	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8415	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8416	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8417	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8418	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8419	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8420	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8421	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8422	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8423	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8424	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8425	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8426	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8427	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8428	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8429	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8430	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8431	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8432	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8433	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8434	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8435	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8436	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8437	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8438	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8439	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8440	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8441	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8442	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8443	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8444	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8445	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8446	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8447	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8448	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8449	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8450	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056	MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8473	Ebselen	NA	Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus	Human immunodeficiency virus	NA	NA	Decrease (50 %)	Investigational	23850693
DrugRepV_8474	2-Phenylbenzo[d]isothiazol-3(2H)-one	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8475	2-Phenylbenzo[d] isoxazol-3(2H)-one	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8476	2-Phenyl isoindolin-1-one	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8477	Chelerythrine chloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8478	Nitidine chloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8479	Berberine chloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8480	Sanguinarine chloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8481	Norsanguinarine chloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8482	R-Apomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8483	S-Apomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8484	R(?)-Propylnorapomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693
DrugRepV_8485	R(?)-Apocodeine hydrochloride	NA	NA	Human immunodeficiency virus	NA	NA	Decrease (50 %)	NA	23850693